Jennison Associates LLC Raises Position in Sionna Therapeutics, Inc. $SION

Jennison Associates LLC lifted its holdings in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) by 11.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,115,278 shares of the company’s stock after acquiring an additional 117,903 shares during the period. Jennison Associates LLC’s holdings in Sionna Therapeutics were worth $45,883,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in SION. Vanguard Group Inc. increased its stake in Sionna Therapeutics by 81.4% in the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after purchasing an additional 512,803 shares during the last quarter. Viking Global Investors LP boosted its stake in Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after buying an additional 242,427 shares during the last quarter. Millennium Management LLC grew its holdings in Sionna Therapeutics by 1,425.5% in the 3rd quarter. Millennium Management LLC now owns 214,085 shares of the company’s stock valued at $6,296,000 after buying an additional 200,051 shares during the period. Geode Capital Management LLC increased its stake in shares of Sionna Therapeutics by 113.4% during the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock valued at $5,020,000 after acquiring an additional 153,712 shares during the last quarter. Finally, Soleus Capital Management L.P. increased its stake in shares of Sionna Therapeutics by 56.7% during the 2nd quarter. Soleus Capital Management L.P. now owns 376,000 shares of the company’s stock valued at $6,524,000 after acquiring an additional 136,000 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts recently issued reports on SION shares. Guggenheim raised their target price on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. UBS Group reaffirmed a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Raymond James Financial reaffirmed a “strong-buy” rating and set a $53.00 price target on shares of Sionna Therapeutics in a research note on Monday, January 5th. Citizens Jmp initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price objective for the company. Finally, BTIG Research restated a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $53.00.

Insider Activity at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 2,948 shares of Sionna Therapeutics stock in a transaction on Saturday, April 18th. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96. Following the transaction, the director owned 2,964,774 shares in the company, valued at approximately $131,991,738.48. The trade was a 0.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 2,948 shares of the company’s stock in a transaction on Saturday, April 18th. The stock was sold at an average price of $44.52, for a total transaction of $131,244.96. Following the sale, the director directly owned 2,964,774 shares of the company’s stock, valued at approximately $131,991,738.48. This trade represents a 0.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,193,762 shares of company stock valued at $53,594,505. 3.90% of the stock is owned by insiders.

Sionna Therapeutics Price Performance

NASDAQ SION opened at $38.70 on Friday. Sionna Therapeutics, Inc. has a 1-year low of $11.67 and a 1-year high of $46.46. The firm has a market capitalization of $1.75 billion, a P/E ratio of -19.85 and a beta of 3.01. The business’s 50-day simple moving average is $38.18 and its 200-day simple moving average is $39.00.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.15. On average, equities research analysts expect that Sionna Therapeutics, Inc. will post -2.44 EPS for the current fiscal year.

Sionna Therapeutics Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.